The funding includes a $40.1M PIPE led by OrbiMed and Marshall Wace, plus $17.9M from warrant exercises. Proceeds will support operations as the company launches its FDA-approved CGuard Prime carotid stent in the U.S.
In parallel, InspireMD named Raymond W. Cohen—former CEO of Axonics and a seasoned medtech executive with multiple billion-dollar exits—to its board. Cohen’s expertise is expected to accelerate InspireMD’s commercial push and strategic expansion.
CEO Marvin Slosman emphasized the company’s momentum: “With a strong balance sheet, national coverage for carotid stenting, and best-in-class clinical data, we are poised to lead the carotid intervention market.”
Follow MEDWIRE.AI for cardiovascular device market insights.
